Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Lind Karin |
Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen
Dutta, S; Rezania, S; Lyssy, F; Lind, K; Vosberg, S; Thallinger, G; Zebisch, A; Wölfler, A; Pabst, G; Foßelteder, J; Reinisch, A; Sill, H;
Deciphering the molecular mechanism of mesenchymal stromal cell mediated drug resistance in acute myeloid leukemia.
29th European Hematology Association Congress; JUN 13-16, 2024; Madrid, SPAIN. 2024.
[Poster]
Lind, K; Dutta, S; Foßelteder, J; Pabst, G; Reinisch, A; Wölfler, A; Zebisch, A; Sill, H;
Deciphering early steps of TP53 aberrant human leukemogenesis.
29th European Hematology Association Congress; JUN 13-16, 2024; Madrid, SPAIN. 2024.
[Poster]
Lyssy, F; Lind, K; Zöscher, F; Zebisch, A; Wölfler, A; Pabst, G; Fosselteder, J; Reinisch, A; Sill, H; Dutta, S
Modelling drug resistance conferred by mono- and bi-allelic TP53 aberrations using isogenic AML cell lines
ONCOL RES TREAT. 2023; 46: 188-189.
[Poster]
Web of Science
FullText
Dutta,S; Moritz,J; Pregartner,G; Thallinger,G; Brandstätter, I; Lind,K; Rezania,S; Lyssy,F; Reinisch,A; Zebisch,A; Berghold,A;Wölfler, A and Sill, H
AML and MDS patients with TP53 aberrations – a single cancer center experience.
Magazine of European Medical Oncology“. 2022; -Frühjahrestagung ÖGHO 2022; APR 8-10 2022; Graz, Austria.
[Oral Communication]
Krall N, Meszaros N, Lind K, Vilagos B, Sill H, Vladimer GI.
Functional Precision Medicine in AML: Technical Performance Evaluation for in Vitro Diagnostics Using High-Throughput Image-Based Screening of Primary Patient Cells
Blood. 2019; 134, Suppl. 1: -American Society of Hematology, Annual Meeting; DEC 6-10, 2019; Orlando.
[Poster]
Kashofer, K; Gornicec, M; Caraffini, V; Lind, K; Schauer, S; Beham-Schmid, C; Wölfler, A; Hoefler, G; Sill, H; Zebisch, A
Genetic aberrations of myeloid sarcomas
memo - Magazine of European Medical Oncology
. 2017; 10(2):28-28.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology
; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]
Lal, R; Lind, K; Kashofer, K; Heitzer, E; Ulz, P; Troppmair, J; Hofer, S; Schulz, E; Mathre, K; Wölfler, A; Zebisch, A; Sill, H
TP53 mutations in acute myeloid leukemia affect pre-leukemic stem cells
memo - Magazine of European Medical Oncology . 2016; 0(1):19-20.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 17-19, 2016; Vienna, AUSTRIA.
[Poster]
Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Rankl, J; Hofer, S; Mueller, M; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Woelfler, A; Zebisch, A; Sill, H
IMPAIRED BASE EXCISION REPAIR GLYCOSYLASE/AP ENDONUCLEASE ACTIVITY CONTRIBUTES TO CYTARABINE RESISTANCE IN ACUTE MYELOID LEUKEMIA
HAEMATOLOGICA. 2016; 101: 211-212.
[Poster]
Web of Science
Schulz, E; Lind, K; Renner, W; Petersen, BS; Dill, C; Hofer, S; Lal, R; Quehenberger, F; Stolzel, F; Sill, H
THE HOMOZYGOUS TP53 P72R SNP IS ASSOCIATED WITH NON-FAVORABLE CYTOGENETIC RISK GROUPS IN ACUTE MYELOID LEUKEMIA
HAEMATOLOGICA. 2016; 101: 383-383.
[Poster]
Web of Science
Zebisch, A; Lal, R; Muller, M; Lind, K; Sill, H
TP53 germline mutations occur in acute myeloid leukemia and are associated with therapy-related cases following ionizing radiation
WIEN KLIN WOCHENSCHR. 2016; 128: S385-S386.
[Poster]
Web of Science
Lind, K; Olipitz, W; Monsberger, N; Katschnig, A; Hofer, S; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Wölfler, A; Zebisch, A; Sill, H
Defizienz der Basen-Exzisions-Reparatur (BER) bei akuter myeloischer Leukämie (AML).
memo-magazine of european medical oncology
2014 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology. 2014; 7(1):-Annual Meeting of the Austrian Society for Haematology and Medical Oncology; APR 10-12, 2014; Innsbruck, AUSTRIA.
[Poster]
Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Hofer, S; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Woelfler, A; Zebisch, A; Sill, H
Base Excision Repair Glycosylase Activity Is Impaired in a Subgroup of Acute Myeloid Leukemia Resulting in Increased Levels of Oxidative Base Lesions
BLOOD. 2014; 124(21):-56th Annual Meeting of the American-Society-of-Hematology; DEC 06-09, 2014; San Francisco, CA.
[Poster]
Web of Science
Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Hofer, S; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Wölfler, A; Zebisch, A; Sill, H
Base excision repair glycosylase activity is impaired in a subgroup of acute myeloid leukemia resulting in increased levels of oxidative base lesions
Oncol Res Treat. 2014; 37(S5):49-49.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 10-14; Hamburg, GERMANY. (ISBN: 978-3-318-02811-9 )
[Poster]
Web of Science
Schulz, E; Valentin, A; Ulz, P; Beham-Schmid, C; Lind, K; Rupp, V; Lackner, H; Wolfler, A; Zebisch, A; Olipitz, W; Geigl, JB; Berghold, A; Speicher, MR; Sill, H
Germ-line mutations in cancer predisposing genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy-related myeloid neoplasms.
ONKOLOGIE. Onkologie. 2012; 35: 117-117.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 19-23, 2012; Stuttgart, GERMANY.
[Poster]
Web of Science
Pichler, M; Fried, I; Bodner, C; Hiden, K; Linkesch, W; Sill, H; Wölfler, A
EZH2-und IDH1/2-Mutationen bei Patienten mit Therapie-assoziierter akuter myeloischer Leukämie (t-AML )
Magazine of European Medical Oncology. 2011; 4(Sup1):12-13.
[Poster]
Schulz, E; Rohn, A; Lind, K; Woelfler, A; Beham-Schmid, C; Guelly, C; Lackner, H; Geigl, J; Speicher, M; Sill, H
Keimbahnmutationen in den DNA-Reparatur und Apoptose-induzierenden Genen BRCA1, BARD1 und TP53 bei Patienten mit Therapie-assoziierten myeloischen Neoplasien.
OeGHO Frühjahrstagung (Young Investigator Meeting); MAY, 5-7, 2011; Pörtschach, AUSTRIA. 2011.
[Oral Communication]
Zebisch, A; Wölfler, A; Hiden, K; Bodner, C; Fried, I; Quehenberger, F; Drasche, A; Pirkebner, D; Rath, O; Blyth, K; Matallanas, D; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
RAF and RKIP in Acute Myeloid Leukemia
Fruehjahrstagung 2011 der Oesterreichischen Gesellschaft fuer Haematologie & Onkologie; Mai 5-7, 2011; Poertschach, AUSTRIA. 2011.
[Oral Communication]
Zebisch, A; Wölfler, A; Hiden K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Haller, M; Matallanas, D; Fried, I; Rath, O; Blyth, K; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
RAF kinase inhibitor protein ist ein neuer Tumor-Suppressor bei der akuten myeloischen Leukämie
Onkologie. 2011; 34(S6):209-209.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; SEP 30-OCT 4, 2011; Basel, Switzerland. (ISBN: 978-3-8055-9922-1 )
[Oral Communication]
Web of Science
FullText
Haller, M; Zebisch, A; Hiden, K; Hoefler, G; Sill, H; Troppmair, J
Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations
FEBS J. 2010; 277: 127-127.
[Poster]
Web of Science
Pichler, M; Bodner, C; Hiden, K; Linkesch, W; Sill, H; Wölfler, A
IDH1 and IDH2 mutations in patients with therapy-related and secondary AML evolving from myelodysplasia.
Memo2010; 3 Suppl. 01/10: 13--Jahrestagung der Österr. Gesellschaft für Hämatologie und Onkologie; Apri 2010; Bregenz.
[Poster]
Zebisch, A; Woelfler, A; Hiden, K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Haller, M; Rath, O; Blyth, K; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
Loss of RAF Kinase Inhibitor Protein Is a Frequent Event In Acute Myeloid Leukemia with a Monocytic Phenotype and Cooperates with Mutant RAS In Malignant Transformation
BLOOD. 2010; 116(21): 1702-1702.
[Poster]
Web of Science
Zebisch, A; Woelfler, A; Hiden, K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Rath, O; Blyth, K; Delwel, R; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
LOSS OF RKIP IN ACUTE MYELOID LEUKEMIA WITH A MONOCYTIC PHENOTYPE
HAEMATOL-HEMATOL J. 2010; 95: 0026 -Annual Meting of the European Haematology Association; June 2010; Barcelona.
[Poster]
Web of Science
Olipitz, W; Scheer, N; Quehenberger, F; Hiden, K; Rankl, J; Schlembach, D; Sill, H
Base Excision Repair Deficiency in Acute Myeloid Leukemia.
BLOOD. 2009; 114(22): 454-454.
[Poster]
Web of Science
FullText
Scheer, N; Olipitz, W; Quehenberger, F; Hiden, K; Rankl, J; Schlembach, D; Sill, H
Impaired base excision repair in acute myeloid leukemia.
Memo2009; 2 (Suppl. 2): -Frühjahrstagung der Österr. Gesellschaft für Hämatologie und Onkologie; April 2009; Salzburg.
[Poster]
Zebisch, A; Haller, M; Hiden, K; Rath, O; Doyle, B; Wölfler, A; Delwel, R; Kolch, W; Troppmair, J; Sill, H
Loss of the tumor suppressor RKIP in acute myeloid leukemia
Memo2009; 2 (Suppl.2): -Frühjahrstagung der Österr. Gesellschaft für Hämnatologie und Onkologie; April 2009; Salzburg.
[Oral Communication]
Zebisch, A; Staber, PB; Fischereder, K; Bodner, C; Hiden, K; Linkesch, W; Auner, HW; Emberger, W; Sovinz, P; Schimek, MG; Höfler, G; Sill, H;
Analysis of the proto-oncogenes A-, B- and C-RAF in acute myeloid leukemia.
The Hematol J. 2004; 5: 2-2.
[Poster]
Zebisch, A; Staber, PB; Fischereder, K; Bodner, C; Hiden, K; Linkesch, W; Auner, HW; Emberger, W; Windpassinger, C; Schimek, MG; Hoefler, G; Troppmair, J; Sill, H
Two novel activating germline mutations of the C-RAF proto-oncogene predisposing to solid tbmors and therapy-related acute myeloid leukemia.
BLOOD 2004 104: 920A-920A.
Doi: 10.1182/blood.V104.11.3370.3370
Web of Science
FullText
FullText_MUG
Zebisch, A; Staber, PB; Fischereder, K; Bodner, C; Hiden, K; Linkesch, W; Auner, HW; Windpassinger, C; Höfler, G; Sill, H;
C-RAF mutations in therapy-related acute myeloid leukemia.
Onkologie. 2004; 27: 118-118.
[Poster]
Olipitz, W; Hopfinger, G; Hoefler, G; Girschikofsky, M; Bodner, C; Hiden, K; Aguiar, R; Linkesch, W; Sill, H
Microsatellite instability but lack of alternations of genes targeted by defective DNA-mismatch repair in therapy-related MDS and leukemia.
BLOOD 2000 96: 104A-104A.
Web of Science